Carregant...
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used a...
Guardat en:
| Publicat a: | J Immunother Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057421/ https://ncbi.nlm.nih.gov/pubmed/32098830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000461 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|